Modified Short-Course Radiotherapy Combined With Immunochemotherapy and Targeted Therapy as First-Line Treatment for MSS Metastatic Colorectal Cancer

This is a single-arm interventional study targeting patients with initially unresectable MSS-type advanced colorectal cancer with liver and/or lung and peritoneal metastasis. Patients will receive lymph node-sparing modified short-course radiotherapy combined with tislelizumab, CAPOX chemotherapy, and bevacizumab targeted therapy, aiming to explore the tumor reactivity and safety of modified short-course radiotherapy combined with immunotherapy and first-line treatment.

NCT Number	NCT07512674
Lead Sponsor	Sir Run Run Shaw Hospital
Conditions	Patients With Initially Unresectable MSS-type Advanced Colorectal Cancer With Liver and/or Lung and Peritoneal Metastasis
Enrollment	33 participants
Start Date	2026-02-26
Primary Completion	2026-12 (estimated)
Study Completion	2027-03 (estimated)
Updated on ClinicalTrials.gov	2026-04-06